Stock Events

Stock Events

PolyPeptide Group 

€0
0
+€0+0% Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

12MarExpected
Q4 2025
0.3
0.63
0.96
1.3
Expected EPS
0.295698748385
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 8H0.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Bank of China
BACHF
Mkt Cap287.37B
Bachem Holding AG specializes in peptide technology, directly competing in the same sector as PolyPeptide.
AMGEN
AMGN
Mkt Cap187.56B
Amgen Inc. develops peptide therapeutics among other biotech solutions, overlapping with PolyPeptide's market.
Lilly(Eli) &
LLY
Mkt Cap837.36B
Eli Lilly and Company, through its acquisition of Prevail Therapeutics, competes in peptide drug development.
Novartis
NVS
Mkt Cap297.32B
Novartis AG engages in significant research in peptide-based drugs, competing for similar market share.
Pfizer
PFE
Mkt Cap161.09B
Pfizer Inc. has investments in peptide research and drug development, positioning it as a competitor.
Roche
RHHBY
Mkt Cap321.08B
Roche Holding AG develops peptide therapeutics, directly competing with PolyPeptide in the biopharmaceutical field.
Sanofi
SNY
Mkt Cap116.63B
Sanofi SA focuses on peptide drug solutions among its diverse biopharmaceutical products, competing with PolyPeptide.
Merck
MRK
Mkt Cap298.84B
Merck & Co., Inc. has a strong focus on innovative drug development including peptides, competing in the same arena.
GSK
GSK
Mkt Cap113.29B
GlaxoSmithKline plc invests in peptide-based drug development, making it a competitor in this specialized field.

About

PolyPeptide Group AG operates as a contract development and manufacturing company in Europe, the United States, Asia Pacific, and internationally. It develops and manufactures synthetic peptides used as active pharmaceutical ingredients or intermediates in therapeutic products. The company offers portfolio of drug therapies for metabolic diseases, including the GLP-1. It also provides generic peptides and peptides used in cosmetics, animal health, and medical devices, as well as development and analytical services. The company serves academic, pharmaceutical, and biotech companies. PolyPeptide Group AG was founded in 1952 and is headquartered in Baar, Switzerland. PolyPeptide Group AG is a subsidiary of Draupnir Holding B.V.
Show more...
CEO
Mr. Juan Jose Gonzalez
Employees
1440
Country
United Kingdom
ISIN
CH1110760852

Listings

F
DE
8H0.F
MU
DE
8H0.MU
STU
DE
8H0.STU
LSE
GB
0AAJ.LSE

0 Comments

Share your thoughts

FAQ

What is PolyPeptide Group stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange PolyPeptide Group stocks are traded under the ticker 8H0.MU.
When is the next PolyPeptide Group earnings date?▼
PolyPeptide Group is going to release the next earnings report on August 13, 2026.
How many employees does PolyPeptide Group have?▼
As of April 12, 2026, the company has 1,440 employees.
In which sector is PolyPeptide Group located?▼
PolyPeptide Group operates in the Manufacturing sector.
When did PolyPeptide Group complete a stock split?▼
PolyPeptide Group has not had any recent stock splits.
Where is PolyPeptide Group headquartered?▼
PolyPeptide Group is headquartered in Baar, United Kingdom.